GLP-1 RA Use and Major Adverse Cardiovascular Events in Patients With Monoclonal Gammopathy of Undetermined Significance
JAMA Network Open · 2025
DOI: 10.1001/jamanetworkopen.2025.17541 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2025. Verfasst von Kuan-Yu Chi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York. Hauptthemen laut MEDLINE: Monoclonal Gammopathy of Undetermined Significance, Cardiovascular Diseases, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.
Abstract (Originalsprache)
Importance Monoclonal gammopathy of undetermined significance (MGUS) is associated with an increased risk of cardiovascular disease. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have demonstrated cardiorenal benefits in patients with type 2 diabetes, but their effectiveness in patients with MGUS remains unexplored.
Objective
To assess the effectiveness of GLP-1 RAs for primary prevention of major adverse cardiovascular and cerebrovascular events (MACCE) in patients with MGUS and diabetes. Design, Setting, and Participants This retrospective cohort study used a propensity score–matched analysis of data from the TriNetX Global Database, encompassing patients diagnosed with diabetes and MGUS between January 1, 2018, and January 13, 2023. Patients with prior heart failure (HF), ischemic heart disease, coronary revascularization, or stroke or transient ischemic attack before MGUS diagnosis were excluded. The cohort was divided into 2 groups: GLP-1 RA users and nonusers at baseline. After 1:1 propensity score matching, GLP-1 RA users and nonusers were compared up to 5 years from the MGUS diagnosis date. Data analyses were completed January 19, 2025. Exposure GLP-1 RA use within 1 year before MGUS diagnosis. Main Outcomes and Measures The primary end point was MACCE, defined as a composite of all-cause mortality, new-onset HF, acute coronary syndrome, and stroke or transient ischemic attack. Secondary end points included individual MACCE components, decompensated HF, and acute kidney injury or end-stage kidney disease.
Results
A total of 4871 patients with MGUS (mean [SD] age, 68.9 [10.1] years; 2366 [48.5%] male) were included (473 GLP-1 RA users and 4398 non-users). A total of 460 users were matched to 460 nonusers, with balanced characteristics (mean [SD] age, 65.0 [10.6] vs 65.1 [11.0] years; 229 [49.7%] male vs 234 [50.8%] male), including 14 patients (3.0%) vs 13 patients (2.8%) identifying as Asian, 8 (21.3%) vs 92 (20.0%) as Black or African American, 25 patients (5.4%) vs 20 patients (4.3%) as Hispanic or Latino, and 243 patients (52.8%) vs 250 patients (54.3%) as White. GLP-1 RA use was associated with a significantly lower risk of MACCE (hazard ratio [HR], 0.75; 95% CI, 0.60-0.93). Significant reductions were also observed in all-cause mortality (HR, 0.57; 95% CI, 0.37-0.87), new-onset HF (HR, 0.69; 95% CI, 0.54-0.90), decompensated HF (HR, 0.60; 95% CI, 0.43-0.84), and acute kidney injury or end-stage kidney disease (HR, 0.73; 95% CI, 0.57-0.92). Conclusions and Relevance The findings of this cohort study of GLP-1 RA use vs no use in patients with MGUS and diabetes suggest the potential of GLP-1 RA for primary prevention of MACCE. These findings warrant further investigation in prospective randomized trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York.
- Section of Neurosurgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Education, Center for Evidence-Based Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
- Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut.
- Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut.
- Weill Cornell Medicine, New York, New York.
Förderung
- NIA NIH HHS
Zitieren
APA
Chi, K. Y., Song, J., Desphande, S., Lee, P. L., Soni, A., Gonzales-Uribe, A., Lessa, Y., Morgan, A. A., Chang, Y., Lin, Y. S., Akman, Z., Nouri, A., Rossi, R., Babapour, G., Varrias, D., Parker, T., Baldassarre, L. A., Jha, A., Muchtar, E., …, & Nanna, M. G. (2025). GLP-1 RA Use and Major Adverse Cardiovascular Events in Patients With Monoclonal Gammopathy of Undetermined Significance. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.17541
Vancouver
Chi KY, Song J, Desphande S, Lee PL, Soni A, Gonzales-Uribe A, et al. GLP-1 RA Use and Major Adverse Cardiovascular Events in Patients With Monoclonal Gammopathy of Undetermined Significance. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.17541
BibTeX
@article{Chi2025,
author = {Chi, Kuan-Yu and Song, Junmin and Desphande, Shweta and Lee, Pei-Lun and Soni, Anushri and Gonzales-Uribe, Antony and Lessa, Yasmin and Morgan, Ahmed Ashraf and Chang, Yu and Lin, Yu-Shiuan and Akman, Zafer and Nouri, Armin and Rossi, Raiza and Babapour, Golsa and Varrias, Dimitrios and Parker, Terri and Baldassarre, Lauren A and Jha, Alokkumar and Muchtar, Eli and Hull, Sarah C and Kwan, Jennifer M and Nanna, Michael G},
title = {GLP-1 RA Use and Major Adverse Cardiovascular Events in Patients With Monoclonal Gammopathy of Undetermined Significance},
journal = {JAMA Network Open},
year = {2025},
doi = {10.1001/jamanetworkopen.2025.17541}
}
EUVIMED